A compound of formula, which is selected from (Ia), (Ib), and (Ic): a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein: m is 0 to 5; n is 0 to 5; each R 1 is independently selected from halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, and (C 1 -C 6)alkoxy(C 1 -C 6)alkyl; R 1a and R 1b, are each independently selected from hydrogen, halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, and (C 1 -C 6)alkoxy(C 1 -C 6)alkyl; R 2 is selected from hydrogen, (C 1 -C 6)alkyl, and (C 1 -C 6)alkoxy(C 1 -C 6)alkyl; or R 1b together with R 2 may form a 5 to 6-membered heterocyclic ring containing 1 to 2 heteroatoms independently selected from N, O and S, at least one of which is N; said heterocyclic ring may be optionally further substituted with 1 to 4 substituents independently selected from halo, cyano, hydroxy, oxo, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkoxy(C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, and halo(C 1 -C 6)alkoxy; R 3 and R 4 are each independently selected from hydrogen, cyano, and (C 1 -C 6)alkyl-, or R 3 and R 4 together form a 3 to 6 membered cycloalkyl ring; R 5 is selected from hydrogen, halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkoxy(C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, NH(C 1 -C 6)alkyl, N((C 1 -C 6)alkyl) 2, C NH(C 1 -C 6)alkyl, C N((C 1 -C 6)alkyl) 2, NHC (C 1 -C 6)alkyl, N((C 1 -C 6)alkyl)C (C 1 -C 6)alkyl), C (C 1 -C 6)alkyl, C O(C 1 -C 6)alkyl, CO 2 H, CONH 2, SO 2 NH(C 1 -C 6)alkyl, and SO 2 N((C 1 -C 6)alkyl) 2; and each R 6 is independently selected from halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkoxy(C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, NH(C 1 -C 6)alkyl, N((C 1 -C 6)alkyl) 2, C NH(C 1 -C 6)alkyl, C N((C 1 -C 6)alkyl) 2, NHC (C 1 -C 6)alkyl, N((C 1 -C 6)alkyl)C (C 1 -C 6)alkyl), C (C 1 -C 6)alkyl, C O(C 1 -C 6)alkyl, CO 2 H, CONH 2, SO 2 NH(C 1 -C 6)alkyl, and SO 2 N((C 1 -C 6)alkyl) 2. m is 0 to 5; n is 0 to 5; each R 1 is independently selected from halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, and (C 1 -C 6)alkoxy(C 1 -C 6)alkyl; R 1a and R 1b, are each independently selected from hydrogen, halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, and (C 1 -C 6)alkoxy(C 1 -C 6)alkyl; R 2 is selected from hydrogen, (C 1 -C 6)alkyl, and (C 1 -C 6)alkoxy(C 1 -C 6)alkyl; or R 1b together with R 2 may form a 5 to 6-membered heterocyclic ring containing 1 to 2 heteroatoms independently selected from N, O and S, at least one of which is N; said heterocyclic ring may be optionally further substituted with 1 to 4 substituents independently selected from halo, cyano, hydroxy, oxo, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkoxy(C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, and halo(C 1 -C 6)alkoxy; R 3 and R 4 are each independently selected from hydrogen, cyano, and (C 1 -C 6)alkyl-, or R 3 and R 4 together form a 3 to 6 membered cycloalkyl ring; R 5 is selected from hydrogen, halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkoxy(C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, NH(C 1 -C 6)alkyl, N((C 1 -C 6)alkyl) 2, C NH(C 1 -C 6)alkyl, C N((C 1 -C 6)alkyl) 2, NHC (C 1 -C 6)alkyl, N((C 1 -C 6)alkyl)C (C 1 -C 6)alkyl), C (C 1 -C 6)alkyl, C O(C 1 -C 6)alkyl, CO 2 H, CONH 2, SO 2 NH(C 1 -C 6)alkyl, and SO 2 N((C 1 -C 6)alkyl) 2; and each R 6 is independently selected from halo, cyano, hydroxy, (C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkoxy(C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, halo(C 1 -C 6)alkoxy, NH(C 1 -C 6)alkyl, N((C 1 -C 6)alkyl) 2, C NH(C 1 -C 6)alkyl, C N((C 1 -C 6)alkyl) 2, NHC (C 1 -C 6)alkyl, N((C 1 -C 6)alkyl)C (C 1 -C 6)alkyl), C (C 1 -C 6)alkyl, C O(C 1 -C 6)alkyl, CO 2 H, CONH 2, SO 2 NH(C 1 -C 6)alkyl, and SO 2 N((C 1 -C 6)alkyl) 2.